Breakthrough cancer pain: Review of prevalence, characteristics and management

Indian Journal of Palliative Care

Volumn 15, Issue 1, 2009, Pages 14-18

  Mishra, Seema ^a   Bhatnagar, Sushma ^a   Chaudhary, Prakash ^a   Rana, Shiv Pratap Singh ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Analgesic ladder; Breakthrough pain; Cancer; Cancer pain

Indexed keywords

EID: 68349160477     PISSN: 09731075     EISSN: 19983735     Source Type: Journal    
DOI: 10.4103/0973-1075.53506     Document Type: Review

References (21)

1. Takeda F. Results of feld testing in Japan of the WHO guidelines on relief of cancer pain. Pain Clin 1986;1:83-9.
2. Ventafridda V, Tamburini M Caraceni, A validation study of the WHO method for relief of cancer pain. Cancer 1987;59:850-6.
3. Zeppetella G, Catherine A, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a Hospice. J Pain Symp Manage 2000;20:87-92.
4. Mercadante S, Radbruch L, Caraceni A, Cherny N, Ksaasa S, Nauck F, et al. Episodic pain, Consensus conference of an expert working group of the European association for Palliative care. Cancer 2002;94:832-9.
5. Portenoy RK, Hagen NA. Breakthrough pain: Defnition, prevalence and characteristics. Pain 1990;41:273-81.
6. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
7. Fine PG, Busch MA Characterization of breakthrough pain by hospice patients and their caregivers. Pain Symp Manage 1998;16:179-83.
8. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, et al. Working Group of an IASP Task Force on Cancer Pain. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;18:177-83.
9. Levy MH. Pharmacological treatment of cancer pain. N Engl J Med 1996;335:1124-32.
10. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64.
11. Svendsen KB, Andersen S, Arnason S, Arnér S, Breivik H, Heiskanen T, et al. Breakthrough pain in malignant and non-malignant diseases: A review of prevalence, characteristics and mechanisms. Eur J Pain 2005;9:195-206.
12. Davis MP, Walsh D. Epidemiology of cancer pain and factors infuencing poor pain control. Am J Hosp Palliat Care 2004;21:137-42.
13. Augusto C, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain 1999;82:63-74.
14. Portenoy RK, Bennett DS, Rauck R, Simon S, Taylor D, Brennan M, et al. Prevalence and characteristics of breakthrough pain in opioid treated patients with chronic noncancer pain. J Pain 2006;7:583-91.
15. Portenoy R, Payne R. Oral transmucosal fentanyl citrate for treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain 1999;79:303-12.
16. Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA, et al. Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate and morphine sulfate immediate release. Pain 2001;91:123-30.
17. Giovambattista Z. An assessment of the safety effcacy and acceptability of Intranasal Fentanyl citrate in the management of Cancer related breakthrough pain: A pilot study. J Pain Symp Manage 2000;20:253-8.
18. Portenoy R. Managing pain in patients with advanced cancer: The role of neuroaxial infusion. Oncology (Williston Park) 1999;13:7-8.
19. Van Dogen RT, Crul BJ, DeBock M. Long term intrathecal infusion of morphine and morphine/bupivacaine in the treatment of cancer pain: A retrospective analysis of 51 cases. Pain 1993;55:119-23.
20. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. Pain 1995;61:391-9.
21. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997;69:1-8.